ReviewFrontiers in toxicology2023
Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy.
Review in Frontiers in toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07554937 (Optimizing Blinking Exercises to Improve Dry Eye Disease in Patients With Glaucoma), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimizing Blinking Exercises to Improve Dry Eye Disease in Patients With Glaucoma
Who cites it
14 citing papers in PubMed.
- Fifteen-Month Outcomes of Preservative-Free Latanoprost Cationic Emulsion in Open-Angle Glaucoma and Ocular Hypertension: Phase III Open-Label Extension of a Randomized Trial.Clinical ophthalmology (Auckland, N.Z.) · 2025Trial
- [Recurrence of herpetic eye disease following cataract surgery: risk factors and prevention].Die Ophthalmologie · 2026Review
- Effects of Trehalose, Sodium Hyaluronate and N-Acetyl Aspartyl-Glutamic Acid Artificial Tears on Ocular Surface Parameters in Glaucoma Patients Receiving Preserved and Preservative-Free Prostaglandins.Journal of clinical medicine · 2026Article
- Prostaglandin analog therapy challenges and innovation in glaucoma therapeutics.Indian journal of ophthalmology · 2026Review
- Safety of subconjunctival allogeneic platelet-rich plasma on normal canine eyes.Frontiers in veterinary science · 2026Article
- A Personal Scientific Journey in Ophthalmology: Twenty-Five Years of Translating Research into Novel Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Neovascular Glaucoma With Persistent Epithelial Defect: Pathophysiology and Surgical Solutions.Cureus · 2025Article
- Article
- Recurrence of herpetic keratouveitis following cataract surgery.International ophthalmology · 2025Review
- Managing Ocular Surface Disease in Glaucoma Treatment: A Systematic Review.Bioengineering (Basel, Switzerland) · 2024Review
- IOP Reduction in Nonhuman Primates by Microneedle Injection of Drug-Free Hydrogel to Expand the Suprachoroidal Space.Translational vision science & technology · 2024Article
- Immune-Mediated Ocular Surface Disease in Diabetes Mellitus-Clinical Perspectives and Treatment: A Narrative Review.Biomedicines · 2024Review
- Role of Inflammation in Canine Primary Glaucoma.Animals : an open access journal from MDPI · 2023Review
- Comparison of In Vitro Corneal Permeation and In Vivo Ocular Bioavailability in Rabbits of Three Marketed Latanoprost Formulations.European journal of drug metabolism and pharmacokinetics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular surface disease (OSD), a disorder affecting the lacrimal and meibomian glands and the corneal and conjunctival epithelium, is a well-known complication of topical glaucoma therapy. OSD can present as a new or pre-existing condition that virtually any anti-glaucoma formulation can exacerbate. As such, both glaucoma and OSD frequently coexist. Typical OSD symptoms include ocular discomfort, redness, burning, and dryness, whereas signs include periorbital and eyelid skin pigmentation, conjunctival scarring, and superficial punctate keratitis. Pressure-lowering eyedrops can cause toxic, allergic, and inflammatory reactions on the ocular surface. The latter can result from either preservatives or direct toxicity from the active molecule. Although usually mild, OSD can cause significant symptoms that lead to poor quality of life, decreased compliance to therapy, glaucoma progression, and worse visual outcomes. Given the chronic nature of glaucoma, lack of curative therapy, and subsequent lifelong treatment, addressing OSD is necessary. This manuscript aims to provide an up-to-date overview of OSD's signs, symptoms, and pathogenic mechanisms from glaucoma therapy toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.